Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical company Zogenix
With that in mind, let's take a closer look at Zogenix's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||San Diego (2006)|
|Market Cap||$234.5 million|
|Trailing-12-Month Revenue||$44.7 million|
|Management||CEO Roger Hawley
Co-Founder/COO Dr. Stephen Farr
|Trailing-12-Month Return on Capital||(139.3%)|
|Cash/Debt||$22.0 million / $52.4 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 38% of the 47 members who have rated Zogenix believe the stock will underperform the S&P 500 going forward.
There's clearly a committed base following of this stock, since the share price is rising despite predictably weak and declining revenues from Sumavel DosePro and a nasty 47.5M share dilutive financing (warrants with a below market strike might as well be shares). Who's that white knight on the horizon? None other than Zohydro, yet another superfluous oral opiate tablet that will fail to take market share from generic hydrocodone and oxycodone. I don't think I'll have to wait until the rundown after the PDUFA next March to close this pick.
If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.